Targeting the IDO1 pathway in cancer: from bench to bedside

Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors. Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells. In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance. We highlight recent preclinical and clinical progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymatic inhibitors, and effector inhibitors.

• Publication year

  2018

• Venue

  Journal of Hematology & Oncology

• Publication date

  2018-08-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-018-0644-yPMID 30068361PMCID 6090955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gut microbiome modulates efficacy of immune checkpoint inhibitors

  2018cited by this paper
• The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.

  2018cited by this paper
• Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

  2018cited by this paper
• Microbiome: Gut microbiota sways response to cancer immunotherapy

  2018cited by this paper
• High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer

  2018cited by this paper
• High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma

  2018cited by this paper
• IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

  2018cited by this paper
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

  2018cited by this paper
• IDO takes a blow

  2018cited by this paper
• Cancer immunotherapy beyond immune checkpoint inhibitors

  2018cited by this paper
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  2018cited by this paper
• miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

  2018cited by this paper
• Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism

  2018cited by this paper
• Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression

  2018cited by this paper
• The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

  2018cited by this paper
• Next generation of immune checkpoint therapy in cancer: new developments and challenges

  2018cited by this paper
• Hypoxia enhances indoleamine 2,3-dioxygenase production in dendritic cells

  2018cited by this paper
• Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

  2018cited by this paper
• Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

  2018cited by this paper
• Heme-containing enzymes and inhibitors for tryptophan metabolism.

  2017cited by this paper
• Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

  2017cited by this paper
• Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia

  2017cited by this paper
• mTOR Signaling in Growth, Metabolism, and Disease.

  2017cited by this paper
• Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.

  2017cited by this paper
• A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

  2017cited by this paper
• Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model

  2017cited by this paper
• mTOR Signaling in Growth, Metabolism, and Disease.

  2017cited by this paper
• Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

  2017cited by this paper
• First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

  2017cited by this paper
• Engineering CAR-T cells

  2017cited by this paper
• Incorporation of functional elements enhances the antitumor capacity of CAR T cells

  2017cited by this paper
• INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

  2017cited by this paper
• Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

  2017cited by this paper
• Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

  2017cited by this paper
• Clinical trials of CAR-T cells in China

  2017cited by this paper
• The development of bispecific antibodies and their applications in tumor immune escape

  2017cited by this paper
• IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment

  2017cited by this paper
• Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

  2017cited by this paper
• Urinary intermediates of tryptophan as indicators of the gut microbial metabolism.

  2017cited by this paper
• A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

  2017cited by this paper
• Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial

  2017cited by this paper
• Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression.

  2017cited by this paper
• Discovery of IDO1 Inhibitors: From Bench to Bedside.

  2017influential reference
• Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells

  2016influential reference
• A phase I study of indoximod in patients with advanced malignancies

  2016cited by this paper
• The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

  2016cited by this paper
• IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

  2016influential reference
• Tolerogenic Phenotype of IFN-γ–Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop

  2016cited by this paper
• Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation

  2016cited by this paper
• IDO1 is an Integral Mediator of Inflammatory Neovascularization

  2016influential reference
• Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.

  2016influential reference
• Combinatorial approach to cancer immunotherapy: strength in numbers

  2016cited by this paper
• Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

  2016cited by this paper
• Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4⁺ T-cells.

  2016cited by this paper
• Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.

  2015cited by this paper
• The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

  2015cited by this paper
• Role of indoleamine 2,3-dioxygenase in health and disease.

  2015cited by this paper
• Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

  2015cited by this paper
• The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity

  2015cited by this paper
• Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

  2015cited by this paper
• Regulation of T cells by mTOR: the known knowns and the known unknowns.

  2015cited by this paper
• Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

  2015cited by this paper
• The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals

  2015cited by this paper
• Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

  2015cited by this paper
• Indoleamine 2,3-dioxygenase vaccination

  2015cited by this paper
• Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer

  2014cited by this paper
• Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy

  2014cited by this paper
• Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

  2014cited by this paper
• A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

  2014cited by this paper
• Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment.

  2014cited by this paper
• Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

  2013cited by this paper
• Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

  2013influential reference
• Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

  2013cited by this paper
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

  2013cited by this paper
• Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase

  2013cited by this paper
• Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

  2013cited by this paper
• IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

  2012cited by this paper
• IDO is a nodal pathogenic driver of lung cancer and metastasis development.

  2012cited by this paper
• IDO inhibits a tryptophan sufficiency signal that stimulates mTOR

  2012cited by this paper
• Tumor suppressor TSC1 is critical for T-cell anergy

  2012cited by this paper
• Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

  2011cited by this paper
• An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

  2011influential reference
• Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

  2011cited by this paper
• Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

  2011cited by this paper
• Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

  2011influential reference
• Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

  2009cited by this paper
• Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

  2008cited by this paper
• Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase.

  2008cited by this paper
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

  2007cited by this paper
• Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma

  2007cited by this paper
• The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1

  2006cited by this paper
• GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

  2005cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

  2005cited by this paper
• Modulation of tryptophan catabolism by regulatory T cells

  2003influential reference
• Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase

  2002cited by this paper
• Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation

  2000cited by this paper
• Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism

  1999cited by this paper
• Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.

  1979cited by this paper

• Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy

  2026cites this paper
• Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer.

  2026cites this paper
• Discovery of imidazole-based apo-IDO1 inhibitors: rational design, synthesis, and biological evaluation.

  2026cites this paper
• Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

  2026cites this paper
• Tryptophan metabolites 3-hydroxykynurenine (3HK) and 3-hydroxyanthranilic acid (3HAA) increase oxidative stress and impair osteoblastic bone formation.

  2026cites this paper
• Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

  2026cites this paper
• Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer

  2026cites this paper
• Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy.

  2026cites this paper
• Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies

  2026cites this paper
• IDO family: the metabolic crossroads connecting immunity, nerves and tumors

  2026cites this paper
• Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.

  2026cites this paper
• Nano drug delivery systems for advanced immune checkpoint blockade therapy

  2025cites this paper
• Investigating the role of IDO1 in tumors: correlating IDO1 expression with clinical pathological features and prognosis in lung adenocarcinoma patients

  2025cites this paper
• Immunomodulatory mechanisms driving tumor escape in Glioblastoma: the central role of IDO and tryptophan metabolism in local and systemic immunotolerance.

  2025cites this paper
• Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells

  2025cites this paper
• Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer

  2025cites this paper
• Advances in the Study of Metabolic Reprogramming in Gastric Cancer

  2025cites this paper
• Preoperative Peripheral Blood Serotonin and Kynurenine Levels Are Associated With Oncological Outcomes in Glioblastoma IDH-wt Patients

  2025cites this paper
• Boron‐Based Functionalities Enhance, the Potency of 2,5‐Dimethylfuran‐Based IDO1 Inhibitors

  2025cites this paper
• A patent review of IDO1 inhibitors for cancer (2023 – present): an update

  2025cites this paper
• Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance

  2025cites this paper
• IL-32–producing CD8+ memory T cells define immunoregulatory niches in human cutaneous leishmaniasis

  2025cites this paper
• Colorectal Cancers and Immunotherapy.

  2025cites this paper
• Expression of indoleamine-2,3-dioxygenase 1 in sebaceous glands and related tumors of the eyelid: a potential diagnostic target

  2025influential citation
• AI-chemometric assisted real-time monitoring of tryptophan fermentation process using a sensor fusion strategy.

  2025cites this paper
• Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine

  2025cites this paper
• Expression of immune checkpoints (IDO and PD-L1) in oral tongue cancer patients: a 10-year retrospective cohort study in Pakistan

  2025cites this paper
• Neutrophil Dynamics in Response to Cancer Therapies

  2025cites this paper
• Promising Gastric Cancer Biomarkers—Focus on Tryptophan Metabolism via the Kynurenine Pathway

  2025cites this paper
• Tumor Microenvironment-Responsive Nano-Immunomodulators for Enhancing Chimeric Antigen Receptor-T Cell Therapy in Lung Cancer.

  2025cites this paper
• Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma

  2025cites this paper
• Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies.

  2025cites this paper
• The AhR regulates IFN-induced immune checkpoints in lung cancer cells through HNRNPH1, an RNA-binding protein, and INCR1, a novel long non-coding RNA

  2025cites this paper
• Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review)

  2025cites this paper
• “Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“

  2025cites this paper
• The Significance of the Microenvironment in T/Nk-Cell Neoplasms

  2025cites this paper
• Skin Immune Responses and Oncogenesis: A Delicate Balance

  2025cites this paper
• The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling

  2025cites this paper
• Inducible tag-free degradation of endogenous proteins with AlissAID and development of a photoactivable inducer

  2025cites this paper
• Dysbiotic oral microbiota-derived kynurenine, induced by chronic restraint stress, promotes head and neck squamous cell carcinoma by enhancing CD8+ T cell exhaustion

  2025cites this paper
• A novel NIR-dependent IDO-inhibiting ethosomes treatment melanoma through PTT/PDT/immunotherapy synergy.

  2025cites this paper
• Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer

  2025cites this paper
• Intestinal metabolites in colitis-associated carcinogenesis: Building a bridge between host and microbiome

  2025cites this paper
• Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design

  2025cites this paper
• PTPN2 Negatively Regulates Macrophage Immune Responses and Cellular Bioenergetics

  2025cites this paper
• The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models.

  2025cites this paper
• Engineering natural killer cells for cancer immunotherapy

  2025cites this paper
• [Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations].

  2025cites this paper
• Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions

  2025cites this paper
• Dual Inhibition of IDO1 and TDO: A Unified Therapeutic Strategy to Combat Alzheimer's Disease and Cancer.

  2025cites this paper
• Carboxymethyl Dextran-Based Biosensor for Simultaneous Determination of IDO-1 and IFN-Gamma in Biological Material

  2025cites this paper
• From heterogeneity to hope: emerging markers in triple-negative breast cancer research

  2025cites this paper
• Biomarkers of pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis through single-cell transcriptomics

  2025cites this paper
• Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

  2025influential citation
• Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

  2025cites this paper
• Efficacy and Safety of First-Line Chemotherapy-Based Combination Therapy for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Taming the immune storm: The pivotal role of tolerogenic dendritic cells in the pathogenesis and treatment of immune thrombocytopenia.

  2025cites this paper
• HDLR-SR-BI Expression and Cholesterol Uptake are Regulated via Indoleamine-2,3-dioxygenase 1 in Macrophages under Inflammation.

  2025cites this paper
• Heat up, silence on: IDO1 gene silencing in THP-1-derived dendritic cells triggered by magnetic hyperthermia

  2025cites this paper
• From Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit

  2025cites this paper
• Breaking Glycolysis Barriers to Immunotherapy with Nanomedicines

  2025cites this paper
• Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma

  2025cites this paper
• Dynamic remodeling of amino acid metabolism in tumor-associated macrophages: Fueling immunosuppression, reshaping tumor niches, and unlocking metabolic checkpoints.

  2025cites this paper
• Immune Evasion in Endometrial Cancer: Unraveling the Latest Mechanisms and Future Directions.

  2025cites this paper
• Hepatic Metabolic Dysregulation as a Potential Amplifier of Leukemogenesis Following mRNA Vaccination: A Novel Mechanistic Hypothesis

  2025cites this paper
• Lymphatic dissemination of HPV-positive oropharyngeal squamous cell carcinoma: underlying mechanisms and treatment innovations

  2025cites this paper
• Immune Checkpoint Molecule Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Expressed in Lymphoma Subtypes With and Without Epstein-Barr Virus.

  2025cites this paper
• 1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models.

  2025cites this paper
• Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression.

  2025cites this paper
• Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

  2025cites this paper
• Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma

  2025cites this paper
• Myeloid metabolism and its role in immunotherapy of cancer

  2025cites this paper
• The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy

  2025cites this paper
• KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis

  2025cites this paper
• Combined Serum IL-6 and CYFRA 21-1 as Potential Biomarkers for Radon-Associated Lung Cancer Risk: A Pilot Study

  2025cites this paper
• Recent Advances and Evolving Strategies of Photothermal Immunotherapy in Pancreatic Cancer Treatment

  2025cites this paper
• Metabolic reprogramming and immune regulation in acute myeloid leukemia

  2025cites this paper
• A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model

  2025cites this paper
• Cellular Potency Optimization of Novel Heme-Binding Imidazo[5,1-b]thiazoles, Imidazo[1,5-a]pyridines and Pyrazines as Potent IDO1 Inhibitors Devoid of Cytochrome P450 Inhibition.

  2025cites this paper
• Targeting STING-induced immune evasion with nanoparticulate binary pharmacology improves tumor control in mice

  2025cites this paper
• Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition

  2025cites this paper
• Synthesis, antibacterial and anticancer activity of azo-based and aminomethylene derivatives of cyclic β-keto sulfones.

  2025cites this paper
• Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression

  2024cites this paper
• KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma

  2024cites this paper
• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

  2024cites this paper
• Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease

  2024cites this paper
• Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity

  2024cites this paper
• Genomic instability as a driver and suppressor of anti-tumor immunity

  2024cites this paper
• Analysis of the progression of cervical cancer in Guatemala- from pre-malignancy to invasive disease

  2024cites this paper
• Single-cell RNA-sequencing of human spleens reveals an IDO-1+ Tolerogenic Dendritic Cell subset in pancreatic cancer patients that is absent in normal individuals.

  2024cites this paper
• Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy.

  2024cites this paper
• HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability

  2024cites this paper
• Epidemiology, Diagnostics, and Therapy of Oral Cancer—Update Review

  2024cites this paper
• Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma

  2024cites this paper
• IDO1-mediated kynurenine production inhibits IGFBP5 signaling to promote 5-fluorouracil-induced senescence escape and chemoresistance in colorectal cancer.

  2024cites this paper
• IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth.

  2024cites this paper
• Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression

  2024cites this paper
• Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases

  2024cites this paper
• Reshaped Local and Systemic Immune Responses Triggered by a Biomimetic Multifunctional Nanoplatform Coordinating Multi-Pathways for Cancer Therapy.

  2024cites this paper
• Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders

  2024cites this paper